While prurigo nodularis (PN) may be a result of several underlying conditions, it is a distinct clinical entity that may persist despite removal of the underlying cause. Several promising agents in phase III trials may provide significant long-term relief.
In Collaboration With Clinical Care Options, LLC
NPs and PAs
This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte Corporation; Novartis Pharmaceuticals Corporation; and Sanofi and Regeneron Pharmaceuticals.
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Benjamin Ungar, MD: consultant/advisor/speaker: Arcutis; researcher: Incyte, Pfizer, Rapt Therapeutics.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 105822D-CT4